Aspirin in Young Psychotic Patients

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

In this double blind randomized clinical trial the investigators are going to exam influence of adjuvant Aspirin therapy on soft neurological signs (Heidelberg scale), positive and negative symptoms (PANSS), cytokine profile and inflammatory factors, as well as on cognition (MoCA) in young psychotic patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinic for Psychiatric Disorders, Dr Laza Lazarevic
• Collaborator: Stanley Medical Research Institute
• Treatments: Aspirin; Pantoprazole

Criteria

Inclusion Criteria:

• 18 to 28 years of life

• diagnostic categories from F 20 to F 29, according to ICD 10 criteria

• duration of illness ≤ 7 years

Exclusion Criteria:

• Substance abuse

• Primary cognitive impairment

• Contraindications and special caution for acetylsalicylic acid and pantoprazole:

hypersensitivity to aspirin and other NSAIDs or pantoprazole, ulcers, gastritis, pregnancy, haemophilia, bleeding disorders, gout, asthma, COPD, bronchospasm induced by NSAIDs, angioedema, urticaria, haemolytic anaemia, use of warfarin or methotrexate, diabetes, reduced function of liver and/or kidney, heart failure, surgical/dental intervention, interactions with certain psychotropic drugs